These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32732784)

  • 21. Trends in treatment of newly treated schizophrenia-spectrum disorder patients in Taiwan from 1999 to 2006.
    Wu CS; Lin YJ; Feng J
    Pharmacoepidemiol Drug Saf; 2012 Sep; 21(9):989-96. PubMed ID: 22416032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization.
    Markowitz M; Karve S; Panish J; Candrilli SD; Alphs L
    BMC Psychiatry; 2013 Oct; 13():246. PubMed ID: 24094241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse events associated with prescription drug cost-sharing among poor and elderly persons.
    Tamblyn R; Laprise R; Hanley JA; Abrahamowicz M; Scott S; Mayo N; Hurley J; Grad R; Latimer E; Perreault R; McLeod P; Huang A; Larochelle P; Mallet L
    JAMA; 2001 Jan 24-31; 285(4):421-9. PubMed ID: 11242426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
    Tiihonen J; Haukka J; Taylor M; Haddad PM; Patel MX; Korhonen P
    Am J Psychiatry; 2011 Jun; 168(6):603-9. PubMed ID: 21362741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.
    Lin D; Thompson-Leduc P; Ghelerter I; Nguyen H; Lafeuille MH; Benson C; Mavros P; Lefebvre P
    CNS Drugs; 2021 May; 35(5):469-481. PubMed ID: 33909272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence to Antipsychotic Therapy: Association With Hospitalization and Medicare Spending Among Part D Enrollees With Schizophrenia.
    Roberto P; Brandt N; Onukwugha E; Perfetto E; Powers C; Stuart B
    Psychiatr Serv; 2017 Nov; 68(11):1185-1188. PubMed ID: 28760097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study.
    Rubio JM; Taipale H; Correll CU; Tanskanen A; Kane JM; Tiihonen J
    Psychol Med; 2020 Jun; 50(8):1356-1367. PubMed ID: 31190660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release.
    Rajagopalan K; O'Day K; Meyer K; Pikalov A; Loebel A
    J Med Econ; 2013 Aug; 16(8):987-96. PubMed ID: 23742620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
    Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders (Money for Medication): a multicentre, open-label, randomised controlled trial.
    Noordraven EL; Wierdsma AI; Blanken P; Bloemendaal AF; Staring AB; Mulder CL
    Lancet Psychiatry; 2017 Mar; 4(3):199-207. PubMed ID: 28236956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population.
    Joshi K; Muser E; Xu Y; Schwab P; Datar M; Suehs B
    J Comp Eff Res; 2018 Aug; 7(8):723-735. PubMed ID: 29722547
    [No Abstract]   [Full Text] [Related]  

  • 34. Health Care Utilization and Treatment Persistence Associated with Oral Paliperidone and Lurasidone in Schizophrenia Treatment.
    Jiang Y; Ni W
    J Manag Care Spec Pharm; 2015 Sep; 21(9):780-92. PubMed ID: 26308225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia.
    Tiihonen J; Tanskanen A; Taipale H
    Am J Psychiatry; 2018 Aug; 175(8):765-773. PubMed ID: 29621900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
    Phuar HL; Begley CE; Chan W; Krause TM
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1140-1150. PubMed ID: 31556823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.
    Rosenheck RA; Krystal JH; Lew R; Barnett PG; Thwin SS; Fiore L; Valley D; Huang GD; Neal C; Vertrees JE; Liang MH;
    Clin Trials; 2011 Apr; 8(2):196-204. PubMed ID: 21270143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.
    Carswell C; Wheeler A; Vanderpyl J; Robinson E
    Clin Drug Investig; 2010; 30(11):777-87. PubMed ID: 20712387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of compliance and persistence measures in predicting clinical and economic outcomes using administrative data from German sickness funds.
    Frey S; Stargardt T
    Pharmacotherapy; 2012 Oct; 32(10):880-9. PubMed ID: 23033227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia.
    Caroff SN; Mu F; Ayyagari R; Schilling T; Abler V; Carroll B
    BMC Psychiatry; 2018 Sep; 18(1):306. PubMed ID: 30249218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.